

Silicos expands biology lab and announces move to new facilities

Company extends its computational fragment based drug design efforts with biology lab.

Diepenbeek, Belgium: 20 July 2009

Today Silicos NV, the Belgian biotech focused on computational fragment based drug discovery, announced that it is taking several steps to increase its biological lab capabilities. First of all, Silicos has strengthened its team with Anke van Gorp, a highly skilled lab technician who will be responsible for the screening of compounds identified by Silicos as part of its internal drug discovery projects. "Our biology lab will enable Silicos to rapidly confirm the results of our computational fragment based drug discovery efforts, thereby shortening the cycle and further speed up the rapid lead discovery, which is key to our business model", commented Hans De Winter, Silicos' CSO.

Silicos is at present leasing lab space from the University of Hasselt in Belgium. As part of a move to further extending its capabilities the company will move into new accommodation on the same research park that combines offices, computer facilities and lab space.

Silicos NV is a privately held biotechnology company with offices at the Research Park of the University of Hasselt in Belgium. Its principal investors are the Limburg Investment Company - LRM, Allegro Investment Fund, Gemma Frisius Fund II, Flemish Innovation Fund and Software Holding and Finance.

For more information please contact:

Jack Elands, PhD

Chief Business Officer

jack.elands@silicos.com

+32 (0) 472 551-366